THOMAS MONATH to Humans
This is a "connection" page, showing publications THOMAS MONATH has written about Humans.
Connection Strength
0.845
-
Japanese Encephalitis: Risk of Emergence in the United States and the Resulting Impact. Viruses. 2023 12 28; 16(1).
Score: 0.024
-
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential. PLoS Pathog. 2022 06; 18(6):e1010658.
Score: 0.022
-
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022 05 16; 132(10).
Score: 0.022
-
A short history of Lassa fever: the first 10-15 years after discovery. Curr Opin Virol. 2019 08; 37:77-83.
Score: 0.018
-
Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 08 16; 35(35 Pt A):4465-4469.
Score: 0.015
-
Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017 03; 17(3):248-250.
Score: 0.015
-
Yellow fever vaccine supply: a possible solution. Lancet. 2016 Apr 16; 387(10028):1599-600.
Score: 0.014
-
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015 Jan 01; 33(1):62-72.
Score: 0.013
-
Yellow fever. J Clin Virol. 2015 Mar; 64:160-73.
Score: 0.013
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
Score: 0.012
-
17D Yellow Fever Virus Vaccine. Am J Trop Med Hyg. 2013 Dec; 89(6):1225.
Score: 0.012
-
Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine. 2013 Nov 04; 31(46):5321-38.
Score: 0.012
-
Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012 Apr; 11(4):427-48.
Score: 0.011
-
Yellow fever vaccine seroconversion in travelers. Am J Trop Med Hyg. 2011 Oct; 85(4):748-9.
Score: 0.010
-
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
Score: 0.010
-
An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
Score: 0.010
-
Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg. 2010 May; 82(5):919-21.
Score: 0.009
-
Introduction: one health perspective. ILAR J. 2010; 51(3):193-8.
Score: 0.009
-
Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol. 2009 Jul; 16(7):1052-9.
Score: 0.009
-
Yellow fever recommendations for tourists to Kenya: a flawed risk assessment. J Travel Med. 2009 Mar-Apr; 16(2):146; author reply 146-7.
Score: 0.009
-
Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009 Mar 04; 27(10):1637-44.
Score: 0.009
-
Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine. 2009 Mar 04; 27(10):1645-50.
Score: 0.009
-
Yellow fever: 100 years of discovery. JAMA. 2008 Aug 27; 300(8):960-2.
Score: 0.008
-
Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]. Vaccine. 2008 Aug 05; 26(33):4107-8.
Score: 0.008
-
Improving vaccine coverage in Africa. Lancet. 2008 Feb 02; 371(9610):386.
Score: 0.008
-
Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29; 357(22):2222-5.
Score: 0.008
-
Treatment of yellow fever. Antiviral Res. 2008 Apr; 78(1):116-24.
Score: 0.008
-
Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine. 2007 Nov 19; 25(47):8077-84.
Score: 0.008
-
Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot. 2006 Dec; 99(5):341-7.
Score: 0.007
-
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006 Apr 25; 103(17):6694-9.
Score: 0.007
-
Lack of transmission of vaccinia virus. Emerg Infect Dis. 2006 Apr; 12(4):698-700.
Score: 0.007
-
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
Score: 0.007
-
New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005 Oct; 18(5):387-94.
Score: 0.007
-
Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14.
Score: 0.007
-
Yellow fever vaccine. Expert Rev Vaccines. 2005 Aug; 4(4):553-74.
Score: 0.007
-
In Memoriam. Patricia Ann Webb (1925-5005). Arch Virol. 2005 Jun; 150(6):1268-70.
Score: 0.007
-
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine. 2005 May 09; 23(25):3301-9.
Score: 0.007
-
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
Score: 0.007
-
Interview with Thomas P. Monath, M.D. Interview by Vicki Glaser. Vector Borne Zoonotic Dis. 2005; 5(3):300-4.
Score: 0.007
-
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004 Nov; 71(5):639-45.
Score: 0.006
-
ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense. Int J Infect Dis. 2004 Oct; 8 Suppl 2:S31-44.
Score: 0.006
-
Challenge model for Helicobacter pylori infection in human volunteers. Gut. 2004 Sep; 53(9):1235-43.
Score: 0.006
-
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
Score: 0.006
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
Score: 0.006
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.006
-
Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever. Clin Infect Dis. 2023 08 22; 77(4):565-573.
Score: 0.006
-
Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 2003 Sep; 9(9):1125-30.
Score: 0.006
-
Traditional and novel approaches to flavivirus vaccines. Int J Parasitol. 2003 May; 33(5-6):567-82.
Score: 0.006
-
Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients. Clin Immunol. 2023 06; 251:109321.
Score: 0.006
-
Preface to the flaviviruses. Adv Virus Res. 2003; 60:ix-xi.
Score: 0.006
-
Preface to volume 60 the flaviviruses: pathogenesis and immunity. Adv Virus Res. 2003; 60:xiii-xiv.
Score: 0.006
-
Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
Score: 0.006
-
Epidemiology and ecology of yellow fever virus. Adv Virus Res. 2003; 61:291-315.
Score: 0.006
-
Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res. 2003; 61:469-509.
Score: 0.006
-
A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2. Emerg Microbes Infect. 2022 Dec; 11(1):2724-2734.
Score: 0.006
-
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
Score: 0.006
-
High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. J Infect Dis. 2022 10 17; 226(8):1401-1406.
Score: 0.006
-
Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am J Trop Med Hyg. 2022 11 14; 107(5):1091-1098.
Score: 0.006
-
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
Score: 0.005
-
Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002 May 15; 34(10):1369-78.
Score: 0.005
-
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. J Infect Dis. 2022 04 19; 225(8):1399-1410.
Score: 0.005
-
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
Score: 0.005
-
Editorial: jennerian vaccination against West Nile virus. Am J Trop Med Hyg. 2002 Feb; 66(2):113-4.
Score: 0.005
-
Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine. 2002 Jan 15; 20(7-8):996-9.
Score: 0.005
-
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
Score: 0.005
-
Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol. 2002; 267:105-38.
Score: 0.005
-
Transcriptomic signatures induced by the Ebola virus vaccine rVSV?G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. Lancet Microbe. 2022 02; 3(2):e113-e123.
Score: 0.005
-
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Emerg Microbes Infect. 2021 Dec; 10(1):651-663.
Score: 0.005
-
Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci. 2001 Dec; 951:1-12.
Score: 0.005
-
Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med. 2001 Aug; 7(8):350-4.
Score: 0.005
-
Yellow fever: an update. Lancet Infect Dis. 2001 Aug; 1(1):11-20.
Score: 0.005
-
West Nile virus vaccine. Curr Drug Targets Infect Disord. 2001 May; 1(1):37-50.
Score: 0.005
-
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001 Feb; 69(2):988-95.
Score: 0.005
-
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
Score: 0.005
-
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine. 2020 11 17; 38(49):7708-7715.
Score: 0.005
-
The Origin of COVID-19 and Why It Matters. Am J Trop Med Hyg. 2020 Sep; 103(3):955-959.
Score: 0.005
-
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of nucleic acid (RNA and DNA) vaccines. Vaccine. 2020 07 22; 38(34):5556-5561.
Score: 0.005
-
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
Score: 0.005
-
Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases. Vaccine. 2019 10 08; 37(43):6248-6254.
Score: 0.005
-
Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev. 1999 Jul; 12(3):383-93.
Score: 0.004
-
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
Score: 0.004
-
Facing up to re-emergence of urban yellow fever. Lancet. 1999 May 08; 353(9164):1541.
Score: 0.004
-
Ecology of Marburg and Ebola viruses: speculations and directions for future research. J Infect Dis. 1999 Feb; 179 Suppl 1:S127-38.
Score: 0.004
-
Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerg Infect Dis. 1998 Oct-Dec; 4(4):698-702.
Score: 0.004
-
Bunyavirus Taxonomy: Limitations and Misconceptions Associated with the Current ICTV Criteria Used for Species Demarcation. Am J Trop Med Hyg. 2018 07; 99(1):11-16.
Score: 0.004
-
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018 07; 18(7):738-748.
Score: 0.004
-
Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. Hum Vaccin Immunother. 2018 04 03; 14(4):994-1002.
Score: 0.004
-
Vaccine development against infection with Helicobacter pylori. Br Med Bull. 1998; 54(1):229-41.
Score: 0.004
-
Early indicators in acute dengue infection. Lancet. 1997 Dec 13; 350(9093):1719-20.
Score: 0.004
-
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017 10 12; 377(15):1438-1447.
Score: 0.004
-
Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 1997 Oct; 15(14):1494-502.
Score: 0.004
-
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
Score: 0.004
-
Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
Score: 0.004
-
Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017 03; 17(3):e101-e106.
Score: 0.004
-
Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J Gen Virol. 2016 Nov; 97(11):2894-2907.
Score: 0.004
-
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine. 2016 12 12; 34(51):6610-6616.
Score: 0.004
-
Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection. Vaccine. 2016 Apr 12; 34(17):1993-9.
Score: 0.004
-
Stability of yellow fever vaccine. Dev Biol Stand. 1996; 87:219-25.
Score: 0.003
-
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis. 1995 Jul; 172(1):161-72.
Score: 0.003
-
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
Score: 0.003
-
Vector-borne emergent disease. Ann N Y Acad Sci. 1994 Dec 15; 740:126-8.
Score: 0.003
-
A manifesto for planetary health. Lancet. 2014 Apr 26; 383(9927):1459.
Score: 0.003
-
Special symposium on mucosal immunity: protection against pathogens. Introduction. Am J Trop Med Hyg. 1994; 50(5 Suppl):1-2.
Score: 0.003
-
Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013 Oct; 19:292-311.
Score: 0.003
-
Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
Score: 0.003
-
Full genomic sequence of the prototype strain (M64) of Rio Bravo virus. J Virol. 2012 Apr; 86(8):4715.
Score: 0.003
-
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011 Aug; 11(8):622-32.
Score: 0.003
-
Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg. 1991 Jul; 45(1):1-43.
Score: 0.003
-
Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis. 2011 Feb 15; 203(4):513-22.
Score: 0.002
-
Imported Lassa fever--reexamining the algorithms. N Engl J Med. 1990 Oct 18; 323(16):1139-41.
Score: 0.002
-
Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis. 1990 May; 161(5):878-82.
Score: 0.002
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
Score: 0.002
-
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
Score: 0.002
-
Detection of yellow fever viral RNA by nucleic acid hybridization and viral antigen by immunocytochemistry in fixed human liver. Am J Trop Med Hyg. 1989 Jun; 40(6):663-8.
Score: 0.002
-
Japanese encephalitis--a plague of the Orient. N Engl J Med. 1988 Sep 08; 319(10):641-3.
Score: 0.002
-
Executive summary of the AVMA One Health Initiative Task Force report. J Am Vet Med Assoc. 2008 Jul 15; 233(2):259-61.
Score: 0.002
-
Teaching "one medicine, one health". Am J Med. 2008 Mar; 121(3):169-70.
Score: 0.002
-
St. Louis encephalitis: lessons from the last decade. Am J Trop Med Hyg. 1987 Nov; 37(3 Suppl):40S-59S.
Score: 0.002
-
Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine. 2007 Sep 17; 25(37-38):6661-71.
Score: 0.002
-
Lassa fever--new issues raised by field studies in West Africa. J Infect Dis. 1987 Mar; 155(3):433-6.
Score: 0.002
-
Type B hepatitis and yellow fever infections in West Africa. Trans R Soc Trop Med Hyg. 1987; 81(1):172-3.
Score: 0.002
-
Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984. Bull World Health Organ. 1987; 65(6):855-60.
Score: 0.002
-
Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis. 1987 Jan-Feb; 9(1):165-75.
Score: 0.002
-
17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007 Apr 12; 25(15):2758-65.
Score: 0.002
-
Aedes albopictus, an exotic mosquito vector in the United States. Ann Intern Med. 1986 Sep; 105(3):449-51.
Score: 0.002
-
Multisite monoclonal immunoassay for dengue viruses: detection of viraemic human sera and interference by heterologous antibody. J Gen Virol. 1986 Apr; 67 ( Pt 4):639-50.
Score: 0.002
-
Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. J Clin Microbiol. 1986 Jan; 23(1):129-34.
Score: 0.002
-
LeDantec virus: identification as a rhabdovirus associated with human infection and formation of a new serogroup. J Gen Virol. 1985 Dec; 66 ( Pt 12):2749-54.
Score: 0.002
-
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis. 2005 Oct 15; 192(8):1362-71.
Score: 0.002
-
Glad tidings from yellow fever research. Science. 1985 Aug 23; 229(4715):734-5.
Score: 0.002
-
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005 Mar; 128(3):764-70.
Score: 0.002
-
Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
Score: 0.002
-
Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis. J Clin Microbiol. 1984 Oct; 20(4):784-90.
Score: 0.002
-
Specific immunoglobulin A antibodies in maternal milk and delayed Helicobacter pylori colonization in Gambian infants. Clin Infect Dis. 2004 Oct 15; 39(8):1155-60.
Score: 0.002
-
Detection of yellow fever virus in serum by enzyme immunoassay. Am J Trop Med Hyg. 1984 Jan; 33(1):151-7.
Score: 0.002
-
High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of infection. Am J Gastroenterol. 2003 Nov; 98(11):2395-402.
Score: 0.002
-
Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J Infect Dis. 2003 Nov 01; 188(9):1263-75.
Score: 0.001
-
Serodiagnosis of western equine encephalitis virus infections: relationships of antibody titer and test to observed onset of clinical illness. J Am Vet Med Assoc. 1983 Aug 15; 183(4):438-40.
Score: 0.001
-
Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis. 2003 Aug 01; 188(3):440-8.
Score: 0.001
-
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003 Mar; 71(3):1608-10.
Score: 0.001
-
Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine. 2002 Dec 13; 21(3-4):194-201.
Score: 0.001
-
Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002 Nov; 51(5):634-40.
Score: 0.001
-
Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun. 2002 Sep; 70(9):5096-106.
Score: 0.001
-
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
Score: 0.001
-
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001 Jul 14; 358(9276):91-7.
Score: 0.001
-
Posttreatment follow-up of Helicobacter pylori infection using a stool antigen immunoassay. Clin Diagn Lab Immunol. 2001 Jul; 8(4):718-23.
Score: 0.001
-
St Louis encephalitis. Quantitative histologic and immunofluorescent studies. Arch Neurol. 1981 Jun; 38(6):329-34.
Score: 0.001
-
Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans R Soc Trop Med Hyg. 1981; 75(2):282-6.
Score: 0.001
-
Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980 Sep; 29(5):912-28.
Score: 0.001
-
Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas. Am J Trop Med Hyg. 1980 Jul; 29(4):624-34.
Score: 0.001
-
Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics. 1999 Oct; 104(4 Pt 1):942-50.
Score: 0.001
-
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 1999 Apr; 116(4):804-12.
Score: 0.001
-
Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Eng. 1999 Apr; 12(4):357-62.
Score: 0.001
-
Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Am J Trop Med Hyg. 1999 Apr; 60(4):587-92.
Score: 0.001
-
Risk of Helicobacter pylori infection among long-term residents in developing countries. Am J Trop Med Hyg. 1999 Feb; 60(2):267-70.
Score: 0.001
-
Arthropod-borne encephalitides in the Americas. Bull World Health Organ. 1979; 57(4):513-33.
Score: 0.001
-
Necrotizing myocarditis in mice infected with Western equine encephalitis virus: Clinical, electrocardiographic, and histopathologic correlations. J Infect Dis. 1978 Jul; 138(1):59-66.
Score: 0.001
-
St. Louis encephalitis in Memphis-Shelby County, Tennessee, 1975: epidemiologic aspects of human cases. South Med J. 1978 Jun; 71(6):633-7.
Score: 0.001
-
Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine. 1997 Mar; 15(4):370-6.
Score: 0.001
-
Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
Score: 0.001
-
Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ. 1975; 52(4-6):577-92.
Score: 0.001
-
Diagnosis of Lassa fever and the isolation and management of patients. Bull World Health Organ. 1975; 52(4-6):707-15.
Score: 0.001
-
Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg. 1974 Nov; 23(6):1140-9.
Score: 0.001
-
Lassa fever and Marburg virus disease. WHO Chron. 1974 May; 28(5):212-9.
Score: 0.001
-
Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol. 1994 Feb; 75 ( Pt 2):417-23.
Score: 0.001
-
A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg. 1973 Nov; 22(6):773-9.
Score: 0.001
-
Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg. 1973 Nov; 22(6):780-4.
Score: 0.001
-
Lassa fever. Trop Doct. 1973 Oct; 3(4):155-61.
Score: 0.001
-
Western equine encephalomyelitis: virulence markers and their epidemiologic significance. Am J Trop Med Hyg. 1993 Sep; 49(3):322-8.
Score: 0.001
-
Lassa fever: a new appraisal. Niger Med J. 1973 Jul; 3(3):162-3.
Score: 0.001
-
Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993 May-Jun; 87(3):337-9.
Score: 0.001
-
Replication of Colorado tick fever virus within human hematopoietic progenitor cells. J Virol. 1993 Apr; 67(4):2389-95.
Score: 0.001
-
The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observations. Bull World Health Organ. 1973; 49(2):113-21.
Score: 0.001
-
The 1970 yellow fever epidemic in Okwoga District Benue Plateau State, Nigeria. 2. Immunity survey to determine geographic limits and origins of the epidemic. Bull World Health Organ. 1973; 49(2):123-8.
Score: 0.001
-
The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity. Bull World Health Organ. 1973; 49(3):235-44.
Score: 0.001
-
Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice. J Infect Dis. 1971 Mar; 123(3):297-300.
Score: 0.001
-
Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol. 1971 Feb; 93(2):122-9.
Score: 0.001
-
Labile serum factor and its effect on arbovirus neutralization. Appl Microbiol. 1971 Jan; 21(1):79-83.
Score: 0.001
-
Comparison of methods for removal of nonspecific inhibitors of arbovirus hemagglutination. Appl Microbiol. 1970 Nov; 20(5):748-53.
Score: 0.001
-
Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol. 1990 Oct; 71 ( Pt 10):2301-6.
Score: 0.001
-
Studies on California encephalitis in Minnesota. Am J Epidemiol. 1970 Jul; 92(1):40-50.
Score: 0.001
-
Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol. 1989 Dec; 40(4):396-9.
Score: 0.001
-
Genetic variation and microevolution of dengue 2 virus in Southeast Asia. Virology. 1989 Oct; 172(2):523-35.
Score: 0.001
-
Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg. 1989 May-Jun; 83(3):401-6.
Score: 0.001
-
Human infections with Tensaw virus in south Florida: evidence that Tensaw virus subtypes stimulate the production of antibodies reactive with closely related Bunyamwera serogroup viruses. Am J Trop Med Hyg. 1988 Jul; 39(1):117-22.
Score: 0.001
-
Human immunodeficiency virus infection in a rural community. J Fla Med Assoc. 1988 May; 75(5):301-4.
Score: 0.001
-
Epidemic yellow fever in eastern Nigeria, 1986. Lancet. 1988 Mar 19; 1(8586):630-3.
Score: 0.001
-
A newly recognized vesiculovirus, Calchaqui virus, and subtypes of Melao and Maguari viruses from Argentina, with serologic evidence for infections of humans and horses. Am J Trop Med Hyg. 1987 Jan; 36(1):114-9.
Score: 0.000
-
Epizootic vesicular stomatitis in Colorado, 1982: infection in occupational risk groups. Am J Trop Med Hyg. 1987 Jan; 36(1):177-82.
Score: 0.000
-
Epizootic vesicular stomatitis in Colorado, 1982: epidemiologic studies along the northern Colorado front range. Am J Trop Med Hyg. 1987 Jan; 36(1):183-8.
Score: 0.000
-
Genetic heterogeneity of yellow fever virus strains from Africa and the Americas. J Gen Virol. 1986 Jan; 67 ( Pt 1):209-13.
Score: 0.000
-
Arbovirus investigations in Argentina, 1977-1980. I. Historical aspects and description of study sites. Am J Trop Med Hyg. 1985 Sep; 34(5):937-44.
Score: 0.000
-
The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984; 62(4):585-90.
Score: 0.000
-
Reported encephalitis associated with California serogroup virus infections in the United States, 1963-1981. Prog Clin Biol Res. 1983; 123:31-41.
Score: 0.000
-
Human arboviral infections in the United States in 1980. J Infect Dis. 1982 Feb; 145(2):283-6.
Score: 0.000
-
Arbovirus subtyping: applications to epidemiologic studies, availability of reagents, and testing services. Am J Epidemiol. 1981 Nov; 114(5):619-31.
Score: 0.000
-
Arbovirus infections among laboratory personnel in Ibadan, Nigeria. Am J Trop Med Hyg. 1981 Jul; 30(4):855-61.
Score: 0.000
-
[Sylvatic yellow fever in Africa recent advances and present approach (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):31-43.
Score: 0.000
-
[Yellow fever in Senegal from 1976 to 1980 (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):45-51.
Score: 0.000
-
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59(6):895-900.
Score: 0.000
-
Yellow fever in the Gambia, 1978--1979: entomological aspects and epidemiological correlations. Am J Trop Med Hyg. 1980 Sep; 29(5):929-40.
Score: 0.000
-
Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification. Ann N Y Acad Sci. 1980; 354:219-37.
Score: 0.000
-
St Louis encephalitis in Ohio, September 1975: clinical and EEG studies in 16 cases. Arch Intern Med. 1979 May; 139(5):561-6.
Score: 0.000
-
Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. Trans R Soc Trop Med Hyg. 1977; 71(1):60-5.
Score: 0.000
-
Epidemiologic investigations of the 1969 epidemic of Venezuelan encephalitis in Ecuador. Am J Epidemiol. 1975 Nov; 102(5):400-13.
Score: 0.000
-
Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic. Arch Pathol. 1975 Nov; 99(11):599-604.
Score: 0.000
-
Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. Am J Trop Med Hyg. 1974 Nov; 23(6):1131-9.
Score: 0.000
-
Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. II. Entomological investigations and viruses isolated. Trans R Soc Trop Med Hyg. 1974; 68(1):39-43.
Score: 0.000
-
Bwamba virus infection: a sero-survey of veterbrates in five ecological zones in Nigeria. Trans R Soc Trop Med Hyg. 1974; 68(6):461-5.
Score: 0.000
-
Lassa fever in Britain: an imported case. Br Med J. 1973 Sep 22; 3(5881):616-7.
Score: 0.000
-
Studies on Tataguine infection in Nigeria. Trop Geogr Med. 1972 Sep; 24(3):298-302.
Score: 0.000